News on Dendreon (Ticker: DNDN) continually updated from thousands of sources around the net.
Thursday Mar 6 | The Motley Fool
Earnings are the lifeblood of a company. They speak to a company's past, present, and most importantly for investors, future.
Trending on the Topix Network
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
The company did sell more of its drug Provenge than expected, showing a sequential improvement of 10% to $74.8 million in sales, but in this video, Motley Fool health-care analyst David Williamson reminds investors that this is still down from the $85.5 million for the company last year.
Toward the end of trading Tuesday, the Dow traded up 1.38 percent to 16,391.81 while the NASDAQ surged 1.83 percent to 4,355.50.
Analysts at Bernstein downgraded Dendreon from "outperform" to "market perform."
Elsewhere, a heavy amount of short interest has stacked up on Dendreon Corporation.
The Dow Jones Industrial Average is sitting with a triple-digit loss at midday, with swelling concerns about Ukraine at the forefront of most traders' minds.
Shares of Dendreon Corp. saw unusually large options trading activity on Monday.
OAO NOVATEK today announced the results of its Board of Directors m... )--Dendreon Corporation today reported results for the fourth quarter and full year ended December 31, 2013.
Dendreon reported a loss of 17 cents per share, which beat the Capital IQ consensus estimate of a loss of 24 cents a share by seven cents.
Midway through trading Monday, the Dow traded down 1.08 percent to 16,145.89 while the NASDAQ tumbled 1.01 percent to 4,264.70.
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding BlackBerry Limited and Dendreon Corp. .
Dendreon shares soar for a change after reporting its fourth-quarter earnings results.
Dendreon will make PROVENGE commercially available to patients within the approved label through Centers of Excellence using its Contract Manufacturing Organization, PharmaCell.
Net loss for the year ended . 'During the fourth quarter, our results were driven by strong growth in our oncology accounts as well as improvements in urology and academic accounts,' said .